Last December, Sanofi announced to the world a delay of about six months for its main vaccine against Covid.
Following a dosage error, the French laboratory was forced to restart the second phase of its clinical trials.
Hopes of having a "French" vaccine in the leading pack then vanished.
Almost a year later, Sanofi is finally getting closer to the goal.
The last phase of its clinical trials started at the end of May, in collaboration with the British GSK, which provides the adjuvant to the vaccine.
Specific studies are also being carried out on the booster vaccination.
In the event of positive results, its recombinant protein vaccine - a technology already used in one of its influenza vaccines - should be available no later than December 2021. Either one year after that of Pfizer-BioNTech, the first on the finish line at the end of 2020.
Read also
Anti-Covid vaccines: what are the differences between Sanofi's “recombinant proteins” and messenger RNA?
However, Sanofi does not intend to limit itself to an extra role.
He intends to pull his pin
This article is for subscribers only.
You have 76% left to discover.
To cultivate one's freedom is to cultivate one's curiosity.
Continue reading your article for € 1 the first month
I ENJOY IT
Already subscribed?
Log in
